US4853332A
(en)
|
1982-10-19 |
1989-08-01 |
Cetus Corporation |
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
|
IE56026B1
(en)
|
1982-10-19 |
1991-03-27 |
Cetus Corp |
Cysteine-depleted muteins of biologically active proteins
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
US4530787A
(en)
|
1984-03-28 |
1985-07-23 |
Cetus Corporation |
Controlled oxidation of microbially produced cysteine-containing proteins
|
US4572798A
(en)
|
1984-12-06 |
1986-02-25 |
Cetus Corporation |
Method for promoting disulfide bond formation in recombinant proteins
|
CA1340265C
(en)
|
1985-01-18 |
1998-12-15 |
Kirston E. Koths |
Oxidation resistant muteins
|
US5116943A
(en)
|
1985-01-18 |
1992-05-26 |
Cetus Corporation |
Oxidation-resistant muteins of Il-2 and other protein
|
US4766106A
(en)
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
US4816440A
(en)
|
1985-09-26 |
1989-03-28 |
Cetus Corporation |
Stable formulation of biologically active proteins for parenteral injection
|
US4863727A
(en)
|
1986-04-09 |
1989-09-05 |
Cetus Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
US5425940A
(en)
|
1986-04-09 |
1995-06-20 |
Cetus Oncology Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
US5098702A
(en)
|
1986-04-09 |
1992-03-24 |
Cetus Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
US4894226A
(en)
|
1986-11-14 |
1990-01-16 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
|
AU3285989A
(en)
|
1987-11-25 |
1989-06-14 |
Cetus Corporation |
Treatment of infections caused by a primary immunodeficiency with interleukin-2
|
US5066489A
(en)
|
1988-03-28 |
1991-11-19 |
Cetus Corporation |
Combination therapy of IL-2 and DTIC for the treatment of melanoma
|
US4902502A
(en)
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
US5153310A
(en)
|
1989-02-28 |
1992-10-06 |
Du Pont Merck Pharmaceutical Company |
Il-2 analogs containing n-linked glycosylation sites
|
NZ234674A
(en)
|
1989-08-02 |
1992-02-25 |
Seragen Inc |
Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
|
US5776427A
(en)
|
1992-03-05 |
1998-07-07 |
Board Of Regents, The University Of Texas System |
Methods for targeting the vasculature of solid tumors
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
WO1997003703A1
(en)
|
1995-07-21 |
1997-02-06 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
|
CA2212702C
(en)
*
|
1995-02-10 |
2010-04-20 |
Leukosite, Inc. |
Mucosal vascular addressins and uses thereof
|
US20040115128A1
(en)
|
1995-09-08 |
2004-06-17 |
Schnitzer Jan E. |
Targeting endothelium for tissue-specific delivery of agents
|
EP1442750B1
(en)
|
1997-11-20 |
2012-08-01 |
Vical Incorporated |
Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
|
JP2001523480A
(ja)
|
1997-11-20 |
2001-11-27 |
バイカル インコーポレイテッド |
サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置
|
US6232287B1
(en)
|
1998-03-13 |
2001-05-15 |
The Burnham Institute |
Molecules that home to various selected organs or tissues
|
US6455677B1
(en)
|
1998-04-30 |
2002-09-24 |
Boehringer Ingelheim International Gmbh |
FAPα-specific antibody with improved producibility
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
US7138103B2
(en)
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
JP2002521053A
(ja)
|
1998-07-28 |
2002-07-16 |
マイクロメット アーゲー |
ヘテロミニ体
|
US6294349B1
(en)
|
1999-03-01 |
2001-09-25 |
University Of Mississippi Medical Ctr. |
Method of diagnosing and monitoring malignant breast carcinomas
|
US6348192B1
(en)
|
1999-05-11 |
2002-02-19 |
Bayer Corporation |
Interleukin-2 mutein expressed from mammalian cells
|
CN100389821C
(zh)
|
1999-10-04 |
2008-05-28 |
希龙公司 |
稳定化的含多肽的液体药物组合物
|
WO2001053354A2
(en)
|
2000-01-20 |
2001-07-26 |
Chiron Corporation |
Methods for treating tumors using a fusion protein comprising il-2- polypeptides and p185-specific binding molecules
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
US6579521B2
(en)
|
2000-10-20 |
2003-06-17 |
Chiron Corporation |
Methods of therapy for HIV infection
|
JP2005501011A
(ja)
|
2001-06-08 |
2005-01-13 |
ユタ ベンチャー ザ セカンド リミテッド パートナーシップ |
組織特異的内皮膜タンパク質
|
CA2456470A1
(en)
|
2001-08-13 |
2003-02-27 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
US20020187512A1
(en)
|
2001-09-10 |
2002-12-12 |
Nagem Ronaldo Alves Pinto |
Crystal structure of human interleukin-22
|
AU2002357784B2
(en)
|
2001-12-04 |
2008-07-31 |
Merck Patent Gmbh |
Immunocytokines with modulated selectivity
|
AU2003280410B8
(en)
|
2002-01-18 |
2009-04-23 |
Zymogenetics, Inc. |
Cytokine receptor zcytor17 multimers
|
US7611700B2
(en)
|
2002-09-09 |
2009-11-03 |
Hanall Pharmaceuticals, Co., Ltd. |
Protease resistant modified interferon alpha polypeptides
|
EP1900753B1
(en)
|
2002-11-08 |
2017-08-09 |
Ablynx N.V. |
Method of administering therapeutic polypeptides, and polypeptides therefor
|
US7521051B2
(en)
|
2002-12-23 |
2009-04-21 |
Medimmune Limited |
Methods of upmodulating adaptive immune response using anti-PD-1 antibodies
|
WO2004081049A1
(en)
*
|
2003-03-10 |
2004-09-23 |
Auckland Uniservices Limited |
Monoclonal antibodies that recognise mucosal addressin cell adhesion molecule-1 (madcam-1), soluble madcam-1 and uses thereof
|
US7569215B2
(en)
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
DE602004031341D1
(de)
|
2003-07-21 |
2011-03-24 |
Transgene Sa |
Multifunktionelle cytokine
|
DK1944318T3
(da)
|
2003-07-21 |
2011-06-14 |
Transgene Sa |
Multifunktionelle cytokiner
|
KR100632985B1
(ko)
|
2003-07-26 |
2006-10-11 |
메덱스젠 주식회사 |
생리활성 조절 단백질의 효능 향상 방법 및 그 예시변이체들
|
US20050069521A1
(en)
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
US8454963B2
(en)
|
2003-11-13 |
2013-06-04 |
Musc Foundation For Research Development |
Tissue targeted complement modulators
|
CA2550998A1
(en)
|
2003-12-22 |
2005-07-14 |
Chiron Corporation |
Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
|
JP4315982B2
(ja)
*
|
2004-01-09 |
2009-08-19 |
ファイザー インコーポレイティッド |
MAdCAMに対する抗体
|
BRPI0508470A
(pt)
|
2004-03-05 |
2007-07-31 |
Chiron Corp |
sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
|
JP4773434B2
(ja)
|
2004-05-19 |
2011-09-14 |
イムノコア リミテッド |
高親和性ny−esot細胞受容体
|
AU2005249540B2
(en)
|
2004-06-02 |
2009-02-19 |
Sidney Kimmel Cancer Center |
Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
|
WO2006081510A2
(en)
|
2005-01-27 |
2006-08-03 |
Novartis Vaccines And Diagnostics Inc. |
Methods for treating renal cell carcinoma
|
KR20070108402A
(ko)
|
2005-02-15 |
2007-11-09 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
화학요법제와 il-2 및 선택적으로 항-cd20 항체의조합물을 사용하여 임파종을 치료하는 방법
|
WO2006096488A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Pharmacia & Upjohn Company Llc |
Composition comprising human igg2 antibody and chelating agent
|
AU2006244885B2
(en)
|
2005-05-09 |
2011-03-31 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
US8124084B2
(en)
|
2005-05-17 |
2012-02-28 |
University Of Connecticut |
Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra
|
EP1904531B1
(en)
*
|
2005-07-08 |
2010-10-06 |
Pfizer Limited |
Madcam antibodies
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
PL1999154T3
(pl)
|
2006-03-24 |
2013-03-29 |
Merck Patent Gmbh |
Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
|
CA2881717C
(en)
|
2006-06-06 |
2018-06-12 |
Cecilia Anna Wilhelmina Geuijen |
Human binding molecules having killing activity against staphylococci and uses thereof
|
EP2038417A2
(en)
|
2006-07-06 |
2009-03-25 |
Merck Patent GmbH |
Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
|
US8470323B2
(en)
|
2007-01-09 |
2013-06-25 |
The Trustees Of The University Of Pennsylvania |
Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display
|
WO2008097439A2
(en)
|
2007-02-07 |
2008-08-14 |
The Trustees Of The University Of Pennsylvania |
Anti-autoimmune antibodies for treatment of pemphigus
|
JP5650406B2
(ja)
|
2007-03-07 |
2015-01-07 |
ユーティーアイ リミテッド パートナーシップ |
自己免疫状態の予防および治療のための組成物および方法
|
WO2008124858A2
(en)
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
US20080260820A1
(en)
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
US8846867B2
(en)
|
2007-06-26 |
2014-09-30 |
The Trustees Of The University Of Pennsylvania |
Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
|
US8906356B2
(en)
|
2007-11-05 |
2014-12-09 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
CA2742926A1
(en)
|
2007-11-28 |
2009-06-04 |
Universite De Montreal |
Pd-1 modulation and uses thereof
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
WO2010029434A1
(en)
|
2008-09-12 |
2010-03-18 |
Isis Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
AU2009290544B2
(en)
|
2008-09-12 |
2015-07-16 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
WO2010040105A2
(en)
|
2008-10-02 |
2010-04-08 |
Trubion Pharmaceuticals, Inc. |
Cd86 antagonist multi-target binding proteins
|
US8343497B2
(en)
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
WO2010046097A1
(en)
|
2008-10-21 |
2010-04-29 |
Merck Patent Gmbh |
Cancer treatments with radiation and immunocytokines
|
EP2382228B1
(en)
|
2009-01-21 |
2020-08-26 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
US8815297B2
(en)
|
2009-03-31 |
2014-08-26 |
Duke University |
Modulation of beta 2 adrenergic receptors by inhibitors of EGLN3 or pVHL
|
EP2464377B1
(en)
|
2009-08-14 |
2016-07-27 |
The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services |
Use of il-15 to increase thymic output and to treat lymphopenia
|
CU23734A1
(es)
|
2009-11-27 |
2011-11-15 |
Centro Inmunologia Molecular |
Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
|
EP2519544A1
(en)
|
2009-12-29 |
2012-11-07 |
Emergent Product Development Seattle, LLC |
Polypeptide heterodimers and uses thereof
|
EP3511342B1
(en)
|
2010-03-10 |
2024-01-17 |
Genmab A/S |
Monoclonal antibodies against c-met
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
WO2011110604A1
(en)
|
2010-03-11 |
2011-09-15 |
Ucb Pharma, S.A. |
Pd-1 antibody
|
MX352929B
(es)
|
2010-11-05 |
2017-12-13 |
Zymeworks Inc |
DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
|
EA037083B1
(ru)
|
2010-11-12 |
2021-02-03 |
Нектар Терапьютикс |
Иммуномодулирующий конъюгат, включающий il-2 и водорастворимые полимеры
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
EP3211001B1
(en)
|
2010-12-22 |
2020-10-07 |
The Board of Trustees of the Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
DK3489255T3
(da)
|
2011-02-10 |
2021-08-23 |
Roche Glycart Ag |
Muterede interleukin-2-polypeptider
|
US20120207733A1
(en)
|
2011-02-14 |
2012-08-16 |
Allergan, Inc. |
Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases
|
US9499605B2
(en)
|
2011-03-03 |
2016-11-22 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
WO2012119093A1
(en)
|
2011-03-03 |
2012-09-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
DK2683395T3
(en)
|
2011-03-11 |
2018-11-19 |
Hopitaux Paris Assist Publique |
USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES
|
BR112013023151A2
(pt)
|
2011-03-11 |
2020-09-15 |
Assistance Publique - Hôpitaux De Paris |
interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
WO2012163519A1
(en)
|
2011-05-27 |
2012-12-06 |
Dutalys |
Antibodies with improved folding stability
|
CN103764665A
(zh)
|
2011-06-28 |
2014-04-30 |
怀特黑德生物医学研究所 |
使用分选酶安装用于蛋白质连接的点击化学柄
|
EP3939613A1
(en)
|
2011-08-11 |
2022-01-19 |
ONO Pharmaceutical Co., Ltd. |
Therapeutic agent for autoimmune diseases comprising pd-1 agonist
|
WO2013043529A1
(en)
|
2011-09-19 |
2013-03-28 |
Emory University |
Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
|
DK2773671T3
(da)
|
2011-11-04 |
2021-11-15 |
Zymeworks Inc |
Udformning af stabilt heterodimert antistof med mutationer i fc-domænet
|
WO2013075066A2
(en)
|
2011-11-18 |
2013-05-23 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
HUE039118T2
(hu)
|
2012-04-27 |
2018-12-28 |
Novo Nordisk As |
Humán cd30 ligandum antigén kötõ proteinek
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
WO2013189516A1
(en)
|
2012-06-18 |
2013-12-27 |
Apeiron Biologics Ag |
Method for treating a gd2 positive cancer
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
CA2876293C
(en)
|
2012-06-27 |
2023-10-10 |
Arthrogen B.V. |
Combination for treating an inflammatory disorder
|
IN2015DN01115A
(pt)
|
2012-07-13 |
2015-06-26 |
Zymeworks Inc |
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
CN104662045B
(zh)
|
2012-08-07 |
2019-04-05 |
罗切格利卡特公司 |
包含两种工程化改造成具有降低的和升高的效应器功能的抗体的组合物改进的免疫疗法
|
WO2014085947A1
(zh)
|
2012-12-05 |
2014-06-12 |
Chiou Shiow-Her |
趋化素-细胞素融合蛋白和其应用
|
WO2014100014A1
(en)
|
2012-12-17 |
2014-06-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Super-2 complexes with antibody to augment il-2 therapy
|
US9657082B2
(en)
|
2013-01-31 |
2017-05-23 |
Thomas Jefferson University |
PD-L1 and PD-L2-based fusion proteins and uses thereof
|
US20150259416A1
(en)
|
2014-03-12 |
2015-09-17 |
Biocrine Ab |
Methods for treating and/or limiting development of diabetes
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
WO2014150600A2
(en)
|
2013-03-15 |
2014-09-25 |
Angelica Therapeutics, Inc. |
Modified toxins
|
BR112015023752B1
(pt)
*
|
2013-03-15 |
2023-11-14 |
Zyngenia, Inc. |
Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
|
US10260038B2
(en)
|
2013-05-10 |
2019-04-16 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
US10611830B2
(en)
|
2013-06-06 |
2020-04-07 |
Hefei Lifeon Pharmaceutical Co. Ltd. |
Human antibody against ED-B domain of fibronectin and uses thereof
|
WO2015066543A1
(en)
|
2013-11-01 |
2015-05-07 |
Board Of Regents, The University Of Texas System |
Targeting her2 and her3 with bispecific antibodies in cancerous cells
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
WO2015191764A1
(en)
|
2014-06-11 |
2015-12-17 |
Molecular Templates, Inc. |
Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same
|
SI3102595T1
(sl)
|
2014-02-06 |
2019-02-28 |
F. Hoffmann-La Roche Ag |
Fuzijske beljakovine z interlevkinom-2 in njihova uporaba
|
EP3105333B1
(en)
|
2014-02-10 |
2020-04-08 |
Emory University |
Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
|
ES2864124T3
(es)
|
2014-03-11 |
2021-10-13 |
Molecular Templates Inc |
Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
|
EP2918285A1
(en)
|
2014-03-11 |
2015-09-16 |
Université Pierre et Marie Curie (Paris 6) |
Interleukin-2 for treating food allergy
|
EP3134102B1
(en)
|
2014-04-24 |
2019-07-03 |
The Board of Trustees of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
EP2963057A1
(en)
|
2014-07-02 |
2016-01-06 |
Calypso Biotech SA |
Antibodies to IL-15
|
SI3172227T1
(sl)
|
2014-07-21 |
2020-02-28 |
Delinia, Inc. |
Molekule, ki selektivno aktivirajo regulatorne T celice, za zdravljenje avtoimunskih bolezni
|
CA2956471A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
ES2847311T3
(es)
|
2014-08-05 |
2021-08-02 |
MabQuest SA |
Reactivos inmunológicos que se unen a PD-1
|
MA40094B1
(fr)
|
2014-08-06 |
2022-05-31 |
Univ Miami |
Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
|
SI3482766T1
(sl)
|
2014-08-11 |
2020-09-30 |
Delinia, Inc. |
Spremenjene variante IL-2, ki selektivno aktivirajo regulatorne T celice za zdravljenje avtoimunskih bolezni
|
JP6800141B2
(ja)
|
2014-08-12 |
2020-12-16 |
マサチューセッツ インスティテュート オブ テクノロジー |
Il−2およびインテグリン結合性fc融合タンパク質による相乗的な腫瘍処置
|
BR112016030670A2
(pt)
|
2014-08-29 |
2017-10-31 |
Hoffmann La Roche |
"imunocitoquina"
|
LT3590962T
(lt)
|
2014-10-23 |
2021-12-27 |
Singh Molecular Medicine, Llc |
Vieno domeno antikūnai, nukreipti prieš viduląstelinius antigenus
|
HUE055460T2
(hu)
|
2014-12-15 |
2021-11-29 |
Univ Washington |
Készítmények és módszerek a célzott citokin bejuttatására
|
ES2881484T3
(es)
|
2014-12-22 |
2021-11-29 |
Pd 1 Acquisition Group Llc |
Anticuerpos anti-PD-1
|
US20160206666A1
(en)
|
2014-12-22 |
2016-07-21 |
Synlogic, Inc. |
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
|
US20170369871A1
(en)
|
2015-01-12 |
2017-12-28 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
MX2017011644A
(es)
|
2015-03-13 |
2017-12-04 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
|
US10059774B2
(en)
|
2015-04-08 |
2018-08-28 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind CD38
|
RU2749113C2
(ru)
|
2015-04-22 |
2021-06-04 |
Куревак Аг |
Содержащая рнк композиция для лечения опухолевых заболеваний
|
EP3292140B1
(en)
|
2015-05-05 |
2022-04-20 |
Rubicon Biotechnology LLC |
Cancer immunotherapeutic
|
GB201507908D0
(en)
|
2015-05-08 |
2015-06-24 |
Philogen Spa |
IL2 and TNF immunoconjugates
|
DK3298043T3
(da)
|
2015-05-18 |
2021-02-15 |
Ab Initio Biotherapeutics Inc |
SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
|
KR20240013282A
(ko)
|
2015-06-10 |
2024-01-30 |
이뮤너티바이오, 인크. |
암을 치료하기 위한 변형된 nk-92 세포
|
CN114133448A
(zh)
|
2015-06-23 |
2022-03-04 |
纪念斯隆-凯特琳癌症中心 |
新型pd-1免疫调节剂
|
AU2016285868B2
(en)
|
2015-06-30 |
2021-11-11 |
Nanotics, Llc |
Compositions and methods related to scavenger particles
|
CN114146056A
(zh)
|
2015-07-29 |
2022-03-08 |
纳米提克斯有限责任公司 |
用于清除可溶性生物分子的模块化组合物及其相关方法
|
US10548987B2
(en)
|
2015-07-31 |
2020-02-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-drug conjugates for targeting CD56-positive tumors
|
JP2018527350A
(ja)
|
2015-09-01 |
2018-09-20 |
イミュンワーク インク.Immunwork Inc. |
血餅形成の予防及び/又は血栓症の治療のための分子構築物
|
KR20180049080A
(ko)
|
2015-09-11 |
2018-05-10 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
생물학적으로 관련된 직교 사이토카인/수용체 쌍
|
JP2018535655A
(ja)
|
2015-09-29 |
2018-12-06 |
アムジエン・インコーポレーテツド |
Asgr阻害剤
|
CA2997963A1
(en)
|
2015-09-29 |
2017-04-06 |
Celgene Corporation |
Pd-1 binding proteins and methods of use thereof
|
KR20180064536A
(ko)
|
2015-10-22 |
2018-06-14 |
일투 파마 |
Il-2의 약학 조성물
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
WO2017070649A1
(en)
|
2015-10-23 |
2017-04-27 |
Junghans Richard P |
Combination methods for immunotherapy
|
US10138298B2
(en)
|
2015-10-23 |
2018-11-27 |
The Regents Of The University Of California |
Anti-IL-2 antibodies and compositions and uses thereof
|
CA3003969A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
EP3903818A1
(en)
|
2015-11-19 |
2021-11-03 |
Revitope Limited |
Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
|
EP3978010A1
(en)
|
2015-12-02 |
2022-04-06 |
Fred Hutchinson Cancer Research Center |
Circular tandem repeat proteins
|
US20170157215A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
KR20180085740A
(ko)
|
2015-12-09 |
2018-07-27 |
에프. 호프만-라 로슈 아게 |
항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
|
WO2017102010A1
(en)
|
2015-12-17 |
2017-06-22 |
Biontech Rna Pharmaceuticals Gmbh |
Novel cytokine fusion proteins
|
US20190002516A1
(en)
|
2015-12-21 |
2019-01-03 |
Hefei Lifeon Pharmaceutical Co., Ltd. |
Drug Design Method, Obtained Drug and Application Thereof
|
IL260218B2
(en)
|
2016-01-11 |
2023-04-01 |
Novartis Ag |
Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins
|
CN108884157A
(zh)
|
2016-01-11 |
2018-11-23 |
苏黎世大学 |
包含针对白介素2的超级激动剂抗体和检查点阻断剂的组合疗法
|
WO2017123675A1
(en)
|
2016-01-11 |
2017-07-20 |
Synlogic, Inc. |
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
|
US10905727B2
(en)
|
2016-01-14 |
2021-02-02 |
Intrexon Actobiotics N.V. |
Compositions and methods for the treatment of type 1 diabetes
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
EP3411414A4
(en)
|
2016-02-05 |
2019-10-23 |
Washington University |
COMPOSITIONS AND METHOD FOR TARGETED CYTOKINE RELIEF
|
JP6991979B2
(ja)
|
2016-02-05 |
2022-03-04 |
オリオニス バイオサイエンシズ ビーブイ |
Cd8結合物質
|
WO2017139570A1
(en)
|
2016-02-12 |
2017-08-17 |
Massachusetts Intitute Of Technology |
Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne
|
ES2718192T3
(es)
|
2016-02-25 |
2019-06-28 |
Provecs Medical Gmbh |
Sistema vector inmunoestimulante novedoso
|
US11248057B2
(en)
|
2016-03-07 |
2022-02-15 |
Vib Vzw |
CD20 binding single domain antibodies
|
CA3017143A1
(en)
|
2016-03-10 |
2017-09-14 |
The Johns Hopkins University |
Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
|
WO2017156720A1
(zh)
|
2016-03-16 |
2017-09-21 |
谢彦晖 |
糖皮质激素联合聚乙二醇修饰的白介素2治疗呼吸道疾病
|
WO2017158436A1
(en)
|
2016-03-17 |
2017-09-21 |
Oslo Universitetssykehus Hf |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
US20190125840A1
(en)
|
2016-04-12 |
2019-05-02 |
Philogen S.P.A. |
Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell
|
EP3443003B1
(en)
|
2016-04-15 |
2020-12-30 |
Philogen S.p.A. |
Non-glycosylated anti-tenascin antibody
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
EP3280725B1
(en)
|
2016-05-04 |
2020-08-26 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
CN109562143A
(zh)
|
2016-05-06 |
2019-04-02 |
王牧林 |
白细胞介素组合及其用途
|
GB201608192D0
(en)
|
2016-05-10 |
2016-06-22 |
Immunovia Ab |
Method, array and use thereof
|
JP7178906B2
(ja)
|
2016-05-19 |
2022-11-28 |
ザ ジェネラル ホスピタル コーポレイション |
ナチュラルキラー細胞および制御性T細胞の活性を強化するためのプラットフォームである、その受容体IL-2Rβに繋ぎ止められたインターロイキン-2
|
JP6943885B2
(ja)
|
2016-05-25 |
2021-10-06 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
投与量レジメンデザインに関する材料および方法
|
WO2017205810A1
(en)
|
2016-05-27 |
2017-11-30 |
Etubics Corporation |
Neoepitope vaccine compositions and methods of use thereof
|
US20190125852A1
(en)
|
2016-06-03 |
2019-05-02 |
Etubics Corporation |
Compositions and methods for tumor vaccination using prostate cancer-associated antigens
|
CA3026345A1
(en)
|
2016-06-03 |
2017-12-07 |
Etubics Corporation |
Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
|
US20190134195A1
(en)
|
2016-06-03 |
2019-05-09 |
Etubics Corporation |
Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseases
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
JP7206190B2
(ja)
|
2016-06-22 |
2023-01-17 |
ダヴィド・クラッツマン |
遺伝的に修飾されたtリンパ球
|
US11141463B2
(en)
|
2016-07-11 |
2021-10-12 |
The National Institute for Biotechnology in the Negev Ltd. |
Fusion proteins with extended serum half life
|
CA3030451C
(en)
|
2016-07-15 |
2023-09-05 |
Etubics Corporation |
Compositions and methods for alphavirus vaccination
|
CA3030447A1
(en)
|
2016-07-15 |
2018-01-18 |
Etubics Corporation |
Compositions and methods for flavivirus vaccination
|
IL264439B1
(en)
|
2016-08-17 |
2024-04-01 |
Factor Bioscience Inc |
A suitable viral preparation containing a synthetic messenger RNA encoding a gene editing protein for use in cancer treatment and a synthetic messenger RNA encoding a gene editing protein for use in therapy
|
GB201614093D0
(en)
|
2016-08-17 |
2016-09-28 |
Autolus Ltd |
Vector
|
WO2018035395A1
(en)
|
2016-08-19 |
2018-02-22 |
Irx Therapeutics, Inc. |
Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
|
EP3512875A2
(en)
|
2016-09-15 |
2019-07-24 |
Quadrucept Bio Limited |
Multimers, tetramers&octamers
|
US10751414B2
(en)
|
2016-09-19 |
2020-08-25 |
Celgene Corporation |
Methods of treating psoriasis using PD-1 binding antibodies
|
JP2019534859A
(ja)
|
2016-09-19 |
2019-12-05 |
セルジーン コーポレイション |
Pd−1結合タンパク質を使用して白斑を治療する方法
|
WO2018057955A1
(en)
|
2016-09-23 |
2018-03-29 |
Elstar Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
EP3519562A4
(en)
|
2016-09-29 |
2020-03-25 |
Nantkwest, Inc. |
NK-92 HLA CLASS I DEFICIENT CELLS WITH REDUCED IMMUNOGENICITY
|
CN110167957A
(zh)
|
2016-11-08 |
2019-08-23 |
德里尼亚公司 |
用于治疗自身免疫疾病的il-2变体
|
MX2019005465A
(es)
|
2016-11-10 |
2019-10-02 |
Nektar Therapeutics |
Metodo de tratamiento de un tumor inmunoterapeutico.
|
US10011269B2
(en)
|
2016-11-30 |
2018-07-03 |
Ford Global Technologies, Llc |
Identifying in-range fuel pressure sensor error
|
EP3554525A4
(en)
|
2016-12-13 |
2020-08-19 |
Delinia, Inc. |
MULTIVALENT REGULATORS T LYMPHOCYTE MODULATORS
|
US20190352361A1
(en)
|
2016-12-15 |
2019-11-21 |
The Brigham And Women`S Hospital, Inc. |
Tissue-based biologics for the treatment of inflammatory and autoimmune disorders
|
IL297617B2
(en)
|
2016-12-22 |
2023-11-01 |
Cue Biopharma Inc |
Multimeric polypeptides modulate T cells and methods for their use
|
US10232053B2
(en)
|
2016-12-30 |
2019-03-19 |
Trieza Therapeutics, Inc. |
Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
|
WO2018129188A1
(en)
|
2017-01-04 |
2018-07-12 |
Nanotics, Llc |
Methods for assembling scavenging particles
|
JP2020504177A
(ja)
|
2017-01-04 |
2020-02-06 |
ナノティックス,エルエルシー |
捕捉粒子をアセンブルするための方法
|
WO2018129346A1
(en)
|
2017-01-06 |
2018-07-12 |
Nantkwest, Inc. |
Genetically modified nk-92 cells with decreased cd96/tigit expression
|
KR20190104048A
(ko)
|
2017-01-06 |
2019-09-05 |
이오반스 바이오테라퓨틱스, 인크. |
종양 괴사 인자 수용체 슈퍼패밀리 (tnfrsf) 효능제를 사용한 종양 침윤 림프구 (til)의 확장 및 til과 tnfrsf 효능제의 치료 조합물
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
JP2020505438A
(ja)
|
2017-01-10 |
2020-02-20 |
ノダス・セラピューティクスNodus Therapeutics |
インテグリン結合性ポリペプチド−Fc融合タンパク質および免疫調節物質を用いる併用がん治療法
|
JP2020514324A
(ja)
|
2017-02-03 |
2020-05-21 |
ユニバーシティ オブ ピッツバーグ −オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
腫瘍溶解性ウイルス療法
|
NZ756674A
(en)
|
2017-02-16 |
2023-06-30 |
Sonnet Biotherapeutics Inc |
Albumin binding domain fusion proteins
|
CA3055040A1
(en)
|
2017-03-01 |
2018-09-07 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy
|
JP2020514375A
(ja)
|
2017-03-15 |
2020-05-21 |
キュー バイオファーマ, インコーポレイテッド |
免疫応答を調節するための方法
|
CN110520436A
(zh)
|
2017-03-15 |
2019-11-29 |
潘迪恩治疗公司 |
靶向免疫耐受性
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
BR112019017329A2
(pt)
|
2017-04-03 |
2020-04-14 |
Hoffmann La Roche |
imunoconjugados, um ou mais polinucleotídeos e vetores, métodos para a produção de um imunoconjugado, tratamento de uma doença e para a estimulação do sistema imunológico, composição, uso do imunoconjugado, invenção e usos da composição
|
WO2018184965A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
CN108686202A
(zh)
|
2017-04-06 |
2018-10-23 |
张晋宇 |
肿瘤免疫疗法
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
MX2019012187A
(es)
|
2017-04-13 |
2019-11-25 |
Hoffmann La Roche |
Un inmunoconjugado de interleuquina-2, un agonista de cd40 y opcionalmente un antagonista de union al eje pd-1 para uso en metodos para tratar cancer.
|
WO2019103857A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
MX2019013202A
(es)
|
2017-05-10 |
2020-01-21 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos de infiltracion de tumor a partir de tumores liquidos y usos terapeuticos de los mismos.
|
WO2018213192A1
(en)
|
2017-05-15 |
2018-11-22 |
University Of Miami |
Materials and methods for subjects at risk for viral reactivation
|
JP2020520671A
(ja)
|
2017-05-24 |
2020-07-16 |
ノバルティス アーゲー |
抗体−サイトカイングラフト化タンパク質及び使用方法
|
EP3630163A4
(en)
|
2017-05-24 |
2021-06-09 |
Pandion Operations, Inc. |
TARGETED IMMUNTOLERANCE
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
US20210277085A1
(en)
|
2017-05-24 |
2021-09-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
AU2018274216A1
(en)
|
2017-05-24 |
2019-12-12 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
US11819517B2
(en)
|
2017-06-05 |
2023-11-21 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
US20200199247A1
(en)
|
2017-06-07 |
2020-06-25 |
Silverback Therapeutics, Inc. |
Antibody conjugates of immune-modulatory compounds and uses thereof
|
US11241485B2
(en)
|
2017-06-12 |
2022-02-08 |
Obsidian Therapeutics, Inc. |
PDE5 compositions and methods for immunotherapy
|
JP7282383B2
(ja)
|
2017-06-14 |
2023-05-29 |
ディンフー バイオターゲット カンパニー リミテッド |
タンパク質性ヘテロ二量体及びその用途
|
CA3067909A1
(en)
|
2017-06-19 |
2018-12-27 |
Medicenna Therapeutics Inc. |
Uses and methods for il-2 superagonists, agonists, and fusions thereof
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
WO2019010224A1
(en)
|
2017-07-03 |
2019-01-10 |
Torque Therapeutics, Inc. |
FUSION MOLECULES TARGETING IMMUNE REGULATORY CELLS AND USES THEREOF
|
CA3066109A1
(en)
|
2017-07-12 |
2019-01-17 |
Synlogic Operating Company, Inc. |
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
|
US20190023760A1
(en)
|
2017-07-24 |
2019-01-24 |
Eth Zurich |
Method for preparing interleukin-2 or interleukin-2 analogues
|
CA3071016A1
(en)
|
2017-08-03 |
2019-02-07 |
Synthorx, Inc. |
Cytokine conjugates for the treatment of autoimmune diseases
|
CA3071211A1
(en)
|
2017-08-04 |
2019-02-07 |
Genmab A/S |
Binding agents binding to pd-l1 and cd137 and use thereof
|
MX2020001513A
(es)
|
2017-08-09 |
2020-08-20 |
Orionis Biosciences Inc |
Agentes de union a clec9a y su uso.
|
WO2019032661A1
(en)
|
2017-08-09 |
2019-02-14 |
Orionis Biosciences Inc. |
CD8 LIAISON AGENTS
|
JP7423511B2
(ja)
|
2017-08-09 |
2024-01-29 |
オリオンズ バイオサイエンス インコーポレイテッド |
Pd-1およびpd-l1結合物質
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
CA3072816A1
(en)
|
2017-08-18 |
2019-02-21 |
Gritstone Oncology, Inc. |
Antigen-binding proteins targeting shared antigens
|
WO2019046815A1
(en)
|
2017-08-31 |
2019-03-07 |
Poseida Therapeutics, Inc. |
TRANSPOSON SYSTEM AND METHODS OF USE
|
WO2019051126A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF
|
JP2021500855A
(ja)
|
2017-09-07 |
2021-01-14 |
キュー バイオファーマ, インコーポレイテッド |
抗原提示ポリペプチドおよびその使用方法
|
EA202090471A1
(ru)
|
2017-09-07 |
2020-06-10 |
Кью Биофарма, Инк. |
Модулирующие т-клетки мультимерные полипептиды и способы их применения
|
AU2018327224A1
(en)
|
2017-09-07 |
2020-04-23 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
|
EP3679145A2
(en)
|
2017-09-08 |
2020-07-15 |
Poseida Therapeutics, Inc. |
Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
|
EP3687580A1
(en)
|
2017-09-27 |
2020-08-05 |
Sigilon Therapeutics, Inc. |
Methods, compositions, and implantable elements comprising active cells
|
CN111148759B
(zh)
|
2017-09-30 |
2023-09-19 |
合肥立方制药股份有限公司 |
结合至纤维连接蛋白b结构域的蛋白
|
US11474271B2
(en)
|
2017-10-24 |
2022-10-18 |
Schlumberger Technology Corporation |
Methods and systems for automated sonic imaging
|
WO2019084284A1
(en)
|
2017-10-27 |
2019-05-02 |
Coneksis, Inc. |
NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS
|
WO2019091384A1
(en)
|
2017-11-08 |
2019-05-16 |
Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. |
Conjugates of biomolecule and use thereof
|
US20220033427A1
(en)
|
2017-11-13 |
2022-02-03 |
Extremochem, Lda |
Neutral glycosylated amides and dianionic glucuronidated acids as stabilizers for biological molecules
|
MX2020004967A
(es)
|
2017-11-17 |
2020-08-27 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes del tumor (til) de aspirados con aguja fina y biopsias por puncion.
|
US20200299349A1
(en)
|
2017-11-21 |
2020-09-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Partial agonists of interleukin-2
|
EP3720871A4
(en)
|
2017-12-06 |
2021-09-15 |
Pandion Operations, Inc. |
TARGETED IMMUNTOLERANCE
|
CA3084262A1
(en)
|
2017-12-06 |
2019-06-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Engineered proteins to enhance sensitivity of a cell to il-2
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
CA3083941A1
(en)
|
2017-12-06 |
2019-06-13 |
Pandion Therapeutics, Inc. |
Il-2 muteins and uses thereof
|
CA3082204A1
(en)
|
2017-12-13 |
2019-06-20 |
Janssen Biotech, Inc. |
Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
|
CA3085765A1
(en)
|
2017-12-15 |
2019-06-20 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
WO2019122882A1
(en)
|
2017-12-19 |
2019-06-27 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
EP3502139A1
(en)
|
2017-12-19 |
2019-06-26 |
Philogen S.p.A. |
Antibodies to tumour antigens
|
CA3086199A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
US20210139557A1
(en)
|
2017-12-20 |
2021-05-13 |
Poseida Therapeutics, Inc. |
Vcar compositions and methods for use
|
JP7336457B2
(ja)
|
2017-12-26 |
2023-08-31 |
ナンジン、ジェンスクリプト、バイオテック、カンパニー、リミテッド |
抗体Fc領域を主鎖として用いた融合タンパク質二量体及びその使用
|
CA3086842A1
(en)
|
2017-12-27 |
2019-07-04 |
Kyowa Kirin Co., Ltd. |
Il-2 variant
|
US20210079106A1
(en)
|
2017-12-28 |
2021-03-18 |
Julius-Maximilians-Universität Würzburg |
TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCgR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCgR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
|
MX2020007046A
(es)
|
2018-01-08 |
2020-09-07 |
Iovance Biotherapeutics Inc |
Procesos para generar productos de linfocitos infiltrantes de tumores (til) enriquecidos para celulas t especificas de antigenos tumorales.
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
EP3737689A4
(en)
|
2018-01-09 |
2021-12-01 |
Cue Biopharma, Inc. |
MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
|
JP2021511348A
(ja)
|
2018-01-24 |
2021-05-06 |
ベイジン パーカンズ オンコロジー カンパニー リミテッド |
サイトカイン融合タンパク質
|
WO2019144309A1
(en)
|
2018-01-24 |
2019-08-01 |
Beijing Percans Oncology Co. Ltd. |
Cytokine Fusion Proteins
|
AR114127A1
(es)
|
2018-03-02 |
2020-07-22 |
Lilly Co Eli |
Anticuerpos agonistas contra pd-1 y usos de estos
|
WO2019173636A1
(en)
|
2018-03-07 |
2019-09-12 |
Poseida Therapeutics, Inc. |
Cartyrin compositions and methods for use
|
JP2021515599A
(ja)
|
2018-03-09 |
2021-06-24 |
アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. |
新規のサイトカインプロドラッグ
|
EP3820499A4
(en)
|
2018-07-09 |
2022-07-13 |
Surrozen Operating, Inc. |
TISSUE-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND THEIR USES
|
MX2021000801A
(es)
|
2018-07-24 |
2021-04-12 |
BioNTech SE |
Agonistas de il2.
|
US20220041713A1
(en)
|
2018-09-18 |
2022-02-10 |
Pandion Operations, Inc |
Targeted immunotolerance
|
WO2020163646A1
(en)
|
2019-02-08 |
2020-08-13 |
Igm Biosciences, Inc. |
Anti-gitr antigen-binding domains and uses thereof
|
US11739146B2
(en)
|
2019-05-20 |
2023-08-29 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
US11095944B2
(en)
|
2019-08-19 |
2021-08-17 |
Roku, Inc. |
Content-modification system with broadcast schedule utilization feature
|
US20210206856A1
(en)
*
|
2019-08-19 |
2021-07-08 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance with a pd-1 agonist
|
EP4107187A1
(en)
|
2020-02-21 |
2022-12-28 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a cd39 effector
|
WO2021168192A2
(en)
|
2020-02-21 |
2021-08-26 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with pd-1 agonists or il-2 muteins
|
TW202227490A
(zh)
|
2020-08-19 |
2022-07-16 |
美商潘迪恩營運公司 |
多重特異性抗pd-1抗體及其用途
|
WO2022082014A2
(en)
|
2020-10-16 |
2022-04-21 |
Pandion Operations, Inc. |
Skin targeted immunotolerance
|
EP4229097A2
(en)
|
2020-10-16 |
2023-08-23 |
Pandion Operations, Inc. |
Kidney targeted immunotolerance
|